Autotaxin-IN-4

• UNSPSC Description:

  Autotaxin-IN-4 (compound 51), extracted from patent WO2018212534A1, is an Autotaxin inhibitor. Autotaxin-IN-4 has the potential to treat idiopathic pulmonary fibrosis[1].

• Target Antigen:

  Phosphodiesterase (PDE)

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/autotaxin-in-4.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(N1CCC(N=NN2)=C2C1)CC3=NC(C4=CN=C(NC5CC6=C(C=CC=C6)C5)N=C4)=NO3

• Molecular Weight:

  443.46

• References & Citations:

  [1]LEE, Dae Yon, et al. NOVEL COMPOUNDS AS AUTOTAXIN INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME. WO2018212534A1.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2156655-86-4